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ABSTRACT
Melanoma is a recalcitrant disease.  Melanoma patients with the BRAF-V600E 
mutation have been treated with the drug vemurafenib (VEM) which targets this 
mutation. However, we previously showed that VEM is not very effective against a 
BRAF-V600E melanoma mutant in a patient-derived orthotopic xenograft (PDOX) 
model.  In contrast, we demonstrated that recombinant methioninase (rMETase) 
which targets the general metabolic defect in cancer of methionine dependence, was 
effective against the BRAF-V600E mutant melanoma PDOX model.  In the present 
study, we demonstrate that rMETase is effective against a BRAF-V600E-negative 
melanoma PDOX which we established.  Forty BRAF-V600E-negative melanoma PDOX 
mouse models were randomized into four groups of 10 mice each: untreated control 
(n = 10); temozolomide (TEM) (25 mg/kg, p.o., 14 consecutive days, n = 10); rMETase 
(100 units, i.p., 14 consecutive days, n = 10); TEM + rMETase (TEM: 25 mg/kg, p.o., 
rMETase: 100 units, i.p., 14 consecutive days, n = 10). All treatments inhibited tumor 
growth compared to untreated control (TEM: p = 0.0003, rMETase: p = 0.0006, TEM/
rMETase: p = 0.0002) on day 14 after initiation. Combination therapy of TEM and 
rMETase was significantly more effective than either mono-therapy (TEM: p = 0.0113, 
rMETase: p = 0.0173). The present study shows that TEM combined with rMETase 
is effective for BRAF-V600E-negative melanoma PDOX similar to the BRAF-V600E-
positive mutation melanoma. These results suggest rMETase in combination with first-
line chemotherapy can be highly effective in both BRAF-V600E-negative as well as 
BRAF-V600E-positive melanoma and has clinical potential for this recalcitrant disease.  
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INTRODUCTION
Melanoma is a recalcitrant cancer [1] with no 
cure for stage III and IV due to many factors including 
drug resistance, tumor heterogeneity and an immune-
suppressed tumor microenvironment [2]. 
Temozolomide (TEM), an alkylating agent, is first-line 
chemotherapy for melanoma but with limited efficacy [1–5]. 
An excessive requirement for methionine (MET) 
termed MET dependence, appears to be a general 
metabolic defect in cancer.  MET restriction therapy, using 
recombinant methioninase (rMETase), sensitized brain 
tumors to TEM in xenografts in nude mice [6]. In a previous 
study, we tested a patient-derived orthotopic xenograft 
(PDOX) nude mouse model of BRAF V600E-mutant 
melanoma and observed the efficacy of rMETase [7]. 
In the present study, we established a PDOX nude 
mouse model with a BRAF-V600E-negative melanoma 
from a patient. We evaluated the efficacy of rMETase and 
rMETase in combination with TEM on the BRAF-V600E-
negative melanoma. 
RESULTS AND DISCUSSION
Temozolomide (TEM) (p = 0.0003), rMETase 
(p = 0.0006) and the combination of TEM/rMETase 
(p = 0.0002) inhibited tumor growth in the BRAF-
V600E-negative PDOX, as measured on day 14 after 
initiation. The combination of TEM and rMETase was 
significantly more effective than TEM (p = 0.0113) 
and rMETase (p = 0.0173) alone. There was no 
significant difference between TEM and rMETase alone 
(p = 0.4274) (Figure 1). 
Post-treatment MET levels in tumors treated with 
rMETase alone (p = 0.0009) or in combination with TEM 
(p = 0.0006) were significantly decreased compared to the 
untreated control (Figure 2), suggesting the lowering of tumor 
MET levels by rMETase is the mechanism of inhibition. 
These results showed that this BRAF-V600E-
negative melanoma PDOX is MET dependent and 
rMETase suppresses its growth, especially in combination 
with first-line chemotherapy TEM.
Slight body weight loss was observed only in the 
combination treatment group, however there were no 
significant difference in body weight between any group 
(Figure 3). There were no animal deaths in any group. 
Histologically, the untreated control tumor was 
mainly comprised of viable cells. The viable cancer cells of 
the untreated control specimen and the treated specimens 
had a similar appearance. The cancer cells display 
epithelioid to slightly spindly morphology, and contain 
moderate amounts of eosinophilic cytoplasm, with some 
cytoplasmic vacuolization present.  Nuclei are moderately 
pleomorphic with 1 to 2 prominent nucleoli. Mitotic 
activity was present. The same slight degree of necrosis 
was observed in tumors treated with TEM and rMETase. In 
contrast, tumors treated with the combination of TEM and 
rMETase showed extensive necrosis (Figure 4).
TEM has been widely used as standard chemotherapy 
for BRAF-V600E-negative melanoma [1–5]. In this study, 
TEM inhibited tumor growth to a certain extent. TEM in 
combination with rMETase was significantly more effective 
than TEM alone, similar to our previous study for VEM 
resistant BRAF-V600E-positive melanoma [7]. 
The present study has important implications since 
this is the first report that TEM combined with rMETase 
Figure 1: Quantitative efficacy of chemotherapy on the BRAF-V600E-negative PDOX. Line graphs show relative tumor 
volume at each point relative to the initial tumor volume for each treatment and control group. *p < 0.02; **p < 0.01. Error bars: ± SD. 
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is effective treatment for melanoma regardless of BRAF-
V600E mutation status. 
Effective individualized therapy requires matching the 
cancer patient with an effective drug. Toward this goal, our 
laboratory pioneered the patient-derived orthotopic xenograft 
(PDOX) nude mouse model with the technique of surgical 
orthotopic implantation (SOI), including breast [8], ovarian [9], 
lung [10], cervical [11, 12], colon [13–15], stomach [16], 
pancreatic [17–21], melanoma [22–26], and sarcoma [27–36]. 
The PDOX model, developed by our laboratory over the past 
30 years, has many advantages over subcutaneous-transplant 
models which are growing ectopically under the skin [37]. 
The PDOX model enables precise, individualized therapy, 
especially for recalcitrant diseases such as melanoma [23] by 
Figure 2: Intra-tumor MET levels. Bar graphs show MET level in each treatment or control group at pre- and post-treatment time 
points. **p < 0.01.
Figure 3: Mouse body weight. Bar graphs show mouse body weight in each treatment or control group at pre- and post-treatment time 
points. 
Oncotarget918www.impactjournals.com/oncotarget
matching the patient tumor to an effective drug identified with 
the PDOX models. 
Methionine dependence is due to excess use of 
methionine for aberrant transmethylation reactions 
[38, 39]. The elevated methionine use in cancer cells has 
been termed the “Hoffman effect” [29, 39] analogous to 
the “Warburg effect” [40] for elevated aerobic glucose use 
in cancer.  The excessive and aberrant use of methionine 
in cancer is observed in [11C]methionine PET imaging, 
where high uptake of [11C]methionine results in a very 
strong and selective tumor signal compared to normal 
tissue background for brain and other cancers [39]. In a 
comparison of MET-PET and fluorodeoxyglucose (FDG)-
PET, MET-PET was found to be superior for glioma [41–
46] suggesting that cancer may have a greater abnormal 
requirement for methionine than glucose [39]. 
Cell lines derived from various cancer types including 
liver, pancreatic ovarian, submaxillary, brain, lung, bladder, 
prostate, breast, kidney, cervical, colon, fibrosarcoma, 
osteosarcoma, rhabdomyosarcoma, leiomyosarcoma, 
neuroblastoma, glioblastoma and melanoma were shown to 
be methionine dependent in contrast to normal cell lines. 
Human patient tumors, including tumors of the colon, 
breast, ovary, prostate, and a melanoma, were also found to 
be methionine dependent in Gelfoam® histoculture [39, 47]. 
We reported recently on efficacy of rMETase against 
Ewing’s sarcoma in a PDOX model.  rMETase effectively 
reduced tumor growth compared to untreated control 
[29]. We also recently reported that TEM combined with 
rMETase could strongly inhibit tumor growth of BRAF-
V600E-positive melanoma PDOX [29].  The occurrence 
of methionine dependence among many diverse cancer 
types suggests that methionine dependence is a general 
phenomena in cancer [39].
Previously-developed concepts and strategies of 
highly-selective tumor targeting can take advantage of 
molecular targeting of tumors, including tissue-selective 
therapy which focuses on unique differences between 
normal and tumor tissues [48–53].
CONCLUSIONS
The present study has demonstrated the efficacy of 
rMETase and the combination of rMETase and TEM on a 
BRAF-V600E-negative melanoma PDOX model. These 
results sugest that both BRAF-V600E-negative as well 
as -positive melanoma are sensitive to rMETase. Further 
PDOX experiments will determine the general efficacy 
of rMETase on melanoma as a prelude to its clinical 
development for this recalcitrant disease.  
Figure 4: Tumor histology. (A) Untreated control. (B) TEM treated. (C) rMETase treated. (D) TEM/rMETase treated. Scale bars: 50 μm. 
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Both classical and novel forms of vitamin D have 
shown efficacy against melanoma progression and 
management, including in the adjuvant setting [54, 55]. 
Future experiments will evaluate rMETase along with 
classical and novel forms of vitamin D. We recently 
reviewed the establishment and properties of PDOX 
models of melanoma [56]. 
MATERIALS AND METHODS
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San 
Diego, CA), 4–6 weeks old, were used in this study. 
Mice were housed in a barrier facility on a high efficacy 
particulate arrestance (HEPA)-filtered rack under standard 
conditions of 12-hour light/dark cycles.  The animals were 
fed an autoclaved laboratory rodent diet. All animal studies 
were conducted in accordance with the principles and 
procedures outlined in the National Institutes of Health 
Guide for the Care and Use of Animals under Assurance 
Number A3873-1. All mouse surgical procedures and 
imaging were performed with the animals anesthetized 
by subcutaneous injection of a ketamine mixture (0.02 ml 
solution of 20 mg/kg ketamine, 15.2 mg/kg xylazine, 
and 0.48 mg/kg acepromazine maleate). The response of 
animals during surgery was monitored to ensure adequate 
depth of anesthesia. The animals were observed on a 
daily basis and humanely sacrificed by CO2 inhalation if 
they met the following humane endpoint criteria: severe 
tumor burden (more than 20 mm in diameter), prostration, 
significant body weight loss, difficulty breathing, 
rotational motion and body temperature drop [7].
Patient-derived tumor
A patient diagnosed with a BRAF-600E-negative 
melanoma of the abdominal wall was resected in the 
Department of Surgery, University of California, Los 
Angels (UCLA). Written informed consent was provided 
by the patient, and the Institutional Review Board 
(IRB#10-001857) of UCLA approved that the patient’s 
resected melanoma could be used for the present study. 
The tumor was designated at PDOX063. 
Establishment of PDOX models of melanoma by 
surgical orthotopic implantation (SOI)
A fresh sample of the melanoma of the patient was 
obtained and transported immediately to the laboratory at 
AntiCancer, Inc., on wet ice. The sample was cut into 5-mm 
fragments and implanted subcutaneously in nude mice. 
After three weeks, the subcutaneously-implanted tumors 
grew to more than 10 mm in diameter. The subcutaneously-
grown tumors were then harvested and cut into small 
fragments (3 mm3). After nude mice were anesthetized 
with the ketamine solution described above, a 5-mm skin 
incision was made on the abdominal wall, which was split 
to make space for the melanoma tissue fragment. A single 
tumor fragment was implanted orthotopically into the space 
to establish the PDOX model. The wound was closed with a 
6-0 nylon suture (Ethilon, Ethicon, Inc., NJ, USA) [23, 24].
Recombinant methionase (rMETase) production
Recombinant L-metionine α-deamino-γ-mercapto-
methane lyase (recombinant methioninase, [rMETase]) [EC 
4.4.1.11] from Pseudomonas putida has been previously 
cloned and was produced in Escherichia coli (AntiCancer, Inc., 
San Diego, CA). rMETase is a homotetrameric PLP enzyme of 
172-kDa molecular mass [57].
Treatment study design in the PDOX model of 
melanoma
PDOX mouse models of BRAF-V600E-negative 
melanoma were randomized into four groups of 10 mice 
each: untreated control (n = 10); TEM (25 mg/kg, oral 
[p.o.], 14 consecutive days, n = 10); rMETase (100 units, 
intraperitoneal [i.p.], 14 consecutive days, n = 10); TEM 
+ rMETase (TEM: 25 mg/kg, p.o., rMETase: 100 units, 
i.p., 14 consecutive days, n = 10). Tumor length and 
width were measured twice a week. Tumor volume was 
calculated with the following formula: Tumor volume 
(mm3) = length (mm) × width (mm) × width (mm) × 1/2. 
Data are presented as mean ± SD. The tumor volume ratio 
is defined at the tumor volume at each point relative to 
pre-treatment tumor volume.
Intra-tumor MET level analysis
Each tumor, untreated or treated, was sonicated 
for 30 seconds on ice and centrifuged at 12,000 rpm for 
10 minutes. Supernatants were collected and protein levels 
were measured using the Coomassie Protein Assay Kit 
(Thermo Scientific, Rockford, IL). Protein levels were 
calculated from the standard curve obtained by protein 
standard, bovine serum albumin (BSA). MET levels were 
determined with an HPLC procedure described previously 
[29, 58]. Standardized MET levels were calculated using 
the following formula: MET level (nmol/mg protein) = 
MET level (nmol/ml) / protein level (mg protein/ml) [7].
Histological examination
Fresh tumor samples, both untreated and treated, 
were fixed in 10% formalin and embedded in paraffin 
before sectioning and staining. Tissue sections (5 μm) 
were deparaffinized in xylene and rehydrated in an 
ethanol series. Hematoxylin and eosin (H&E) staining was 
performed according to standard protocols. Histological 
examination was performed with a BHS System 
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Microscope (Olympus Corporation, Tokyo, Japan). Images 
were acquired with INFINITY ANALYZE software 
(Lumenera Corporation, Ottawa, Canada) [23–26].
Statistical analysis
JMP version 11.0 was used for all statistical 
analyses. Significant differences for continuous variables 
were determined using the Mann-Whitney U test. Line 
graphs express average values and error bars show SD. A 
probability value of P ≤ 0.05 was considered statistically 
significant [7].
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